Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.[1] It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer.[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency.[1]

References

  1. ^ a b c Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E (2016). "New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?". OncoTargets and Therapy. 9: 6065–6074. doi:10.2147/OTT.S97644. PMC 5063481. PMID 27785053.